Cat. No.: HY-164099

LSD1/HDAC6-IN-2

Customer Review

Based on 1 Customer Validation

LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC₅₀ values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma.

For research use only. We do not sell to patients.

Purity: 99.66%
CAS No.: 2982787-50-6
Formula: C₂₁H₂₃BrN₄O₂
Molecular Weight:443.34

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

LSD1/HDAC6-IN-2 Chemical Structure

CAS No.: 2982787-50-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

HDAC6

11 nM (IC₅₀)

MAO-A

5 nM (IC₅₀)

MAO-B

6600 nM (IC₅₀)

LSD1

5 nM (IC₅₀)

All HDAC Isoforms :

All Monoamine Oxidase Isoforms :

MAO-A
MAO-B

All Histone Demethylase Isoforms :

In Vitro

LSD1/HDAC6-IN-2 (JBI-802) exhibits growth inhibitory activity against multiple myeloma cells MM.1S, MM.1R, and RPMI-8226, with EC₅₀values of 2 nM, 6 nM, and 280 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LSD1/HDAC6-IN-2 (JBI-802) (25 mg/kg; once daily; 12 days; p.o.) exhibits anti-tumor activity in multiple myeloma mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Multiple myeloma cells MM.1S xenograft mice model^[1].
Dosage:

25 mg/kg
Administration:

Oral gavage (p.o.); once daily; 12 days
Result:

Had an oral bioavailability of 44% and exhibited strong anti-cancer effects on the MM.1S xenograft model, surpassing HDAC6 inhibitor ACY-1215 (HY-16026) and LSD1 inhibitor GSK-2879552 (HY-18632).

Chemical Information

CAS No. 2982787-50-6
Appearance Solid
Molecular Weight 443.34
Formula C₂₁H₂₃BrN₄O₂
Color Off-white to light yellow
SMILES

ONC(C(C=C1)=CC=C1CN(N=C2)C=C2CN[C@H]3[C@H](C4=CC=CC=C4)C3)=O.[H]Br
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (225.56 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2556 mL

11.2780 mL

22.5561 mL

5 mM

0.4511 mL

2.2556 mL

4.5112 mL

10 mM

0.2256 mL

1.1278 mL

2.2556 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yang X. Research progress of LSD1-based dual-target agents for cancer therapy. Bioorg Med Chem. 2024 Mar 1;101:117651. [Content Brief]

[2]. Sivanandhan D, et al. JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer[J]. Cancer Research, 2020, 80(16_Supplement): 1756-1756.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2556 mL	11.2780 mL	22.5561 mL	56.3901 mL
	5 mM	0.4511 mL	2.2556 mL	4.5112 mL	11.2780 mL
	10 mM	0.2256 mL	1.1278 mL	2.2556 mL	5.6390 mL
	15 mM	0.1504 mL	0.7519 mL	1.5037 mL	3.7593 mL
	20 mM	0.1128 mL	0.5639 mL	1.1278 mL	2.8195 mL
	25 mM	0.0902 mL	0.4511 mL	0.9022 mL	2.2556 mL
	30 mM	0.0752 mL	0.3759 mL	0.7519 mL	1.8797 mL
	40 mM	0.0564 mL	0.2820 mL	0.5639 mL	1.4098 mL
	50 mM	0.0451 mL	0.2256 mL	0.4511 mL	1.1278 mL
	60 mM	0.0376 mL	0.1880 mL	0.3759 mL	0.9398 mL
	80 mM	0.0282 mL	0.1410 mL	0.2820 mL	0.7049 mL
	100 mM	0.0226 mL	0.1128 mL	0.2256 mL	0.5639 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

LSD1/HDAC6-IN-2

Bioactive Compound Library Max

Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Neuronal Signaling Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Osteogenesis Compound Library

Metabolic Enzyme Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Anti-Brain Cancer Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

All HDAC Isoforms

All Monoamine Oxidase Isoforms

All Histone Demethylase Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

LSD1/HDAC6-IN-2 Related Classifications

HY-164099 Related Classifications